Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,024.09 20.57 (1.97%) as of 4:30 Wed 7/3


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 107.21(B)
Last Volume: 378,341 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 191,758 236,826 311,409 468,643
Total Sell Value $188,359,854 $231,314,072 $294,701,490 $404,818,815
Total People Sold 7 13 16 18
Total Sell Transactions 16 39 65 127
End Date 2024-04-04 2024-01-02 2023-07-04 2022-07-04

   
Records found: 2433
  Page 68 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Brown Michael S Director   –       •      –    2012-11-14 4 S $147.03 $1,029,210 D/D (7,000) 14,662     -
   Brown Michael S Director   –       •      –    2012-11-14 4 OE $23.84 $166,880 D/D 7,000 21,662     -
   Sing George L Director   –       •      –    2012-11-13 4 S $148.00 $740,000 D/D (5,000) 132,772     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2012-11-13 4 AS $144.36 $962,634 D/D (6,537) 87,133     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2012-11-13 4 D $146.60 $735,932 D/D (5,020) 93,670     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2012-11-13 4 OE $8.50 $341,195 D/D 8,176 95,357     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2012-11-08 4 S $138.59 $2,099,221 D/D (15,144) 14,990     -
   Roberts William VP Regulat Dev & Med Safety   •       –      –    2012-11-05 4 GA $0.00 $0 I/I 26,000 45,947     -
   Roberts William VP Regulat Dev & Med Safety   •       –      –    2012-11-05 4 GD $0.00 $0 D/D 26,000 16,644     -
   Ryan Arthur F Director   –       •      –    2012-11-01 4 S $145.57 $1,455,700 D/D (10,000) 40,355     -
   Brown Michael S Director   –       •      –    2012-10-26 4 S $154.69 $464,070 D/D (3,000) 14,662     -
   Brown Michael S Director   –       •      –    2012-10-26 4 OE $23.84 $71,520 D/D 3,000 17,662     -
   Schleifer Leonard S President & CEO   •       •      –    2012-10-25 4 GD $0.00 $0 I/I 75,938 0     -
   Van Plew Daniel P SVP & General Mgr Industrial O   •       –      –    2012-10-25 4 D $159.55 $2,559,661 D/D (16,043) 23,525     -
   Van Plew Daniel P SVP & General Mgr Industrial O   •       –      –    2012-10-25 4 OE $21.92 $657,600 D/D 30,000 39,568     -
   Brown Michael S Director   –       •      –    2012-10-25 4 S $155.34 $310,680 D/D (2,000) 14,662     -
   Brown Michael S Director   –       •      –    2012-10-25 4 OE $23.84 $47,680 D/D 2,000 16,662     -
   Vagelos P Roy Chairman of the Board   •       •      –    2012-10-09 4 GD $0.00 $0 I/I 1,392 162,657     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2012-09-19 4 AS $146.89 $1,056,204 D/D (7,177) 30,134     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2012-09-18 4 D $148.78 $1,163,906 D/D (7,823) 37,311     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2012-09-18 4 OE $16.80 $252,000 D/D 15,000 45,134     -
   Baker Charles A Director   –       •      –    2012-09-06 4 AS $150.00 $2,057,100 D/D (13,714) 9,590     -
   Baker Charles A Director   –       •      –    2012-09-06 4 OE $15.01 $205,847 D/D 13,714 23,304     -
   Baker Charles A Director   –       •      –    2012-09-05 4 AS $150.00 $192,900 D/D (1,286) 9,590     -
   Baker Charles A Director   –       •      –    2012-09-05 4 OE $15.01 $19,303 D/D 1,286 10,876     -
  2433 Records found
  Previous  60  61  62  63  64  65  66  67  68  69  Next   
  Page 68 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us